liposomal mitoxantrone

DRUG3 trials

Sponsors

The First Affiliated Hospital of Soochow University, Institute of Hematology & Blood Diseases Hospital, China

Conditions

AMLDiffuse Large B-Cell LymphomaEpigenetic RepressionPeripheral T Cell Lymphoma

Phase 2

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

The First Affiliated Hospital of Soochow UniversityDiffuse Large B-Cell Lymphoma

Start: 2022-09-30End: 2025-12-31Target: 23Updated: 2023-04-21

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

RecruitingNCT05958719

Institute of Hematology & Blood Diseases Hospital, ChinaEpigenetic Repression, Peripheral T Cell Lymphoma

Start: 2023-03-02End: 2027-03-02Target: 37Updated: 2024-12-30

Unknown Phase

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

Not yet recruitingNCT07490288

Institute of Hematology & Blood Diseases Hospital, ChinaAML

Start: 2026-03-01End: 2029-03-01Target: 30Updated: 2026-03-24

Related Papers

Dual epigenetic modulation with obinutuzumab/liposomal mitoxantrone in refractory or Relapsed Diffuse large B-cell lymphoma patients post-salvage therapy: A phase II study

Blood2025-11-03

A Phase II Study of Dual Epigenetic Agents Plus Obinutuzumab-Mitoxantrone Liposome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Failure of Salvage Immunochemotherapy

Blood2024-11-05